Covidien COV today announced that a subsidiary of the Company filed an answer and counterclaims against Applied Medical Resources Corporation for patent misuse, non-infringement and invalidity.
The action is related to Applied's recent claim against unspecified Versaport Plus trocar products for alleged infringement of a reissue patent, which was issued on May 17, 2011, and will expire February 10, 2013. The reissue patent is based on U.S. Patent 5,407,433 which was previously invalidated when a Federal Court granted a motion for summary judgment by a Covidien affiliate.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in